MX2010012576A - Nuevos polipeptidos cd83 solubles, formulaciones y metodos de uso. - Google Patents

Nuevos polipeptidos cd83 solubles, formulaciones y metodos de uso.

Info

Publication number
MX2010012576A
MX2010012576A MX2010012576A MX2010012576A MX2010012576A MX 2010012576 A MX2010012576 A MX 2010012576A MX 2010012576 A MX2010012576 A MX 2010012576A MX 2010012576 A MX2010012576 A MX 2010012576A MX 2010012576 A MX2010012576 A MX 2010012576A
Authority
MX
Mexico
Prior art keywords
seq
amino acid
hcd83ext
scd83
cell
Prior art date
Application number
MX2010012576A
Other languages
English (en)
Spanish (es)
Inventor
Stephen Brand
Chih-Hsiung Chou
Murray Moo-Young
Original Assignee
Argos Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Argos Therapeutics Inc filed Critical Argos Therapeutics Inc
Publication of MX2010012576A publication Critical patent/MX2010012576A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
MX2010012576A 2008-05-23 2009-05-22 Nuevos polipeptidos cd83 solubles, formulaciones y metodos de uso. MX2010012576A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12870908P 2008-05-23 2008-05-23
PCT/US2009/003174 WO2009142759A1 (en) 2008-05-23 2009-05-22 Novel soluble cd83 polypeptides, formulations and methods of use

Publications (1)

Publication Number Publication Date
MX2010012576A true MX2010012576A (es) 2011-04-05

Family

ID=41340432

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010012576A MX2010012576A (es) 2008-05-23 2009-05-22 Nuevos polipeptidos cd83 solubles, formulaciones y metodos de uso.

Country Status (12)

Country Link
US (1) US20110182903A1 (enExample)
EP (1) EP2288387B1 (enExample)
JP (1) JP2011520959A (enExample)
KR (2) KR20160104101A (enExample)
CN (1) CN102036690B (enExample)
AU (1) AU2009249540B9 (enExample)
BR (1) BRPI0913577B1 (enExample)
CA (1) CA2725198A1 (enExample)
IL (1) IL209207A (enExample)
MX (1) MX2010012576A (enExample)
RU (1) RU2535340C2 (enExample)
WO (1) WO2009142759A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1422241A1 (en) 2002-11-19 2004-05-26 Alexander Steinkasserer Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases
US9102726B2 (en) 2002-12-04 2015-08-11 Argos Therapeutics, Inc. Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same
US7169898B2 (en) 2002-12-04 2007-01-30 Alexander Steinkasserer Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells
CN103243119B (zh) * 2013-05-20 2016-03-30 中国科学技术大学 可溶性cd83的表达和制备方法
CA3042683A1 (en) 2016-11-07 2018-05-11 Coimmune, Inc. Bispecific antibodies that modulate tlr-4 signaling and uses thereof
CN110475571B (zh) 2017-04-01 2023-04-04 Avm生物技术有限责任公司 细胞免疫疗法前细胞毒性预调理的替代
KR102282341B1 (ko) 2018-09-12 2021-07-27 아주대학교산학협력단 Cd83 억제제를 유효성분으로 포함하는 베체트병의 예방 또는 치료용 조성물
EP3895723A1 (en) * 2020-04-16 2021-10-20 Friedrich-Alexander-Universität Erlangen-Nürnberg Scd83 for wound healing, hair growth, and skin and hair care
DE102024110866A1 (de) 2024-04-18 2025-10-23 Christian Arnold Pharmazeutische Zusammensetzung zur Heilung einer Wunde

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US5710262A (en) * 1992-04-17 1998-01-20 Dana-Faber Cancer Institute, Inc. Nucleic acid encoding HB15 polypeptides
US5316920A (en) * 1992-04-17 1994-05-31 Dana-Faber Cancer Institute, Inc. Lymphocyte activation antigen HB15, a member of the immunoglobulin superfamily
CA2301660A1 (en) * 1997-08-26 1999-03-04 Zymogenetics, Inc. Adipocyte-specific protein homologs
ATE297217T1 (de) 1999-10-27 2005-06-15 Alexandra Lucas Zusammensetzung zur vorbeugung und behandlung von transplantatabstossung
US20020014242A1 (en) * 2000-07-31 2002-02-07 Abraham Scaria Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products
US20040185040A1 (en) * 2001-11-21 2004-09-23 Celltech R & D Limited Modulating immune responses
US20030219436A1 (en) * 2002-03-15 2003-11-27 Ledbetter Jeffrey A. Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
US20050032725A1 (en) * 2002-10-09 2005-02-10 Toerrx, Inc. Molecules preferentially associated with effector T cells or regulatory T cells and methods of their use
EP1422241A1 (en) * 2002-11-19 2004-05-26 Alexander Steinkasserer Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases
US7169898B2 (en) * 2002-12-04 2007-01-30 Alexander Steinkasserer Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells
US9102726B2 (en) * 2002-12-04 2015-08-11 Argos Therapeutics, Inc. Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same
CN104177464B (zh) * 2006-08-18 2017-04-12 阿哥斯医疗公司 Cd83在联合治疗中的用途

Also Published As

Publication number Publication date
IL209207A0 (en) 2011-01-31
BRPI0913577A2 (pt) 2020-08-18
IL209207A (en) 2014-05-28
JP2011520959A (ja) 2011-07-21
EP2288387A4 (en) 2011-04-27
HK1155066A1 (en) 2012-05-11
RU2010152553A (ru) 2012-06-27
EP2288387B1 (en) 2013-02-13
US20110182903A1 (en) 2011-07-28
KR20160104101A (ko) 2016-09-02
RU2535340C2 (ru) 2014-12-10
AU2009249540A8 (en) 2011-01-20
CN102036690B (zh) 2013-11-06
EP2288387A1 (en) 2011-03-02
CA2725198A1 (en) 2009-11-26
AU2009249540B2 (en) 2014-07-03
AU2009249540A1 (en) 2009-11-26
WO2009142759A1 (en) 2009-11-26
AU2009249540B9 (en) 2014-09-18
KR101679084B1 (ko) 2016-11-24
BRPI0913577B1 (pt) 2022-05-31
KR20110018381A (ko) 2011-02-23
CN102036690A (zh) 2011-04-27

Similar Documents

Publication Publication Date Title
AU2009249540B9 (en) Novel soluble CD83 polypeptides, formulations and methods of use
CA2295318A1 (en) Human extracellular matrix proteins
JP2018522547A (ja) Ｉｌ−３７バリアント
CA3171638A1 (en) Single-arm actriia and actriib heteromultimers and methods for treating renal diseases or conditions
WO1999049038A2 (en) Human calcium-binding proteins
US5932712A (en) Annexin binding protein
WO1998055600A2 (en) New human ribonuclease
US5945306A (en) Ras protein
WO1998030690A1 (en) Novel human membrane protein
CA2332379A1 (en) Molecules associated with apoptosis
US5962263A (en) Human membrane recycling proteins
WO1998056912A1 (en) Human formin binding protein
HK1155066B (en) Novel soluble cd83 polypeptides, formulations and methods of use
WO1998050546A2 (en) B cell receptor associated proteins
WO1998041634A1 (en) Human growth and differentiation protein
CA2330546A1 (en) Immune system molecules
WO1998054319A1 (en) Metal response element binding protein
WO2009030093A1 (fr) Fonctions et utilisations de l'inhibiteur 2 de la protéine phosphatase 1 humaine
WO1998056911A1 (en) Human phosphatidylinositol transfer protein gamma
US6677126B2 (en) Antibody for human translational regulator
WO2000005368A1 (en) Human calcium regulatory proteins
EP1789450A1 (en) Use of ilt6 for immunomodulation
EP1390391A1 (en) Transporters and ion channels
CA2345881A1 (en) Bone marrow-derived serum proteins
EP1097206A1 (en) Human calcium regulatory proteins

Legal Events

Date Code Title Description
FG Grant or registration